<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441671</url>
  </required_header>
  <id_info>
    <org_study_id>R19017M</org_study_id>
    <secondary_id>2019-002109-24</secondary_id>
    <secondary_id>KLnro 38/2019</secondary_id>
    <nct_id>NCT04441671</nct_id>
  </id_info>
  <brief_title>Oral Pyrophosphate Absorption in PXE Disease</brief_title>
  <official_title>Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hungarian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification.
      The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi).
      Absorption curves (pharmacokinetics), AUC0-t, Cmax and Tmax for PPi and phosphate will be
      provided for healthy controls and PXE-patients both fasting and with standard meal intake.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II oral capsulized disodium-PPi (Na2H2PPi) powder absorption study in subjects with PXE
      (n=8-12) will be done in the ward of Internal Medicine of Tampere University Hospital and
      University Medical Center Utrecht.

      After a 10-hour fast at 8.00 a.m. 30 mg/kg (first day) and 50 mg/kg (second day) capsulized
      dose of PPi will be given with 2 dl water. At 12.00 a.m. another capsulized 30 mg/kg (first
      day) or 50 mg/kg (second day) single dose of PPi with a standard mixed meal (lunch) will be
      given with 2 dl water at the time when a subject starts eating.

      Plasma and urine sampling include plasma and spot urine electrolytes, creatinine, and
      pyrophosphate. Plasma sampling will be done at 0, 15, 30, 60, 120 and 240 min after ingestion
      of PPi. Urine spot sample will be taken at 0 and 240 min after ingestion of PPi.

      Physical activity is restricted. Side-effects will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 4, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absorption pharmacokinetics of pyrophosphate (PPi)</measure>
    <time_frame>two days</time_frame>
    <description>AUC0-t</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absorption pharmacokinetics of pyrophosphate (PPi)</measure>
    <time_frame>two days</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption pharmacokinetics of pyrophosphate (PPi)</measure>
    <time_frame>two days</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption pharmacokinetics of phosphate (Pi)</measure>
    <time_frame>two days</time_frame>
    <description>AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption pharmacokinetics of phosphate (Pi)</measure>
    <time_frame>two days</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption pharmacokinetics of phosphate (Pi)</measure>
    <time_frame>two days</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pseudoxanthoma Elasticum</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Disodiumpyrophosphate, capsuled powder, First day: 30 mg/kg fasting at 08.00 and with standard mixed meal at 12.00 Second day: 50 mg/kg fasting at 08.00 and with standard mixed meal at 12.00</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Disodium Pyrophosphate</intervention_name>
    <description>Absorption trial</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (&gt;18 yrs)

          -  clinically and genetically proven PXE

          -  Body mass index (BMI) 18,5-34,9 kg/m2

        Exclusion Criteria:

          -  Special groups according to researchers' decision.

          -  Pregnancy

          -  No effective contraception in females in child-bearing age.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pasi I Nevalainen, MD, PhD</last_name>
    <phone>+3583311611</phone>
    <email>pasi.nevalainen@pshp.fi</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoxanthoma Elasticum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only anonymized data can be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

